
Releases
Harbour BioMed Wins $20M Patent Case Against Amgen
A Delaware jury has ruled that Amgen and its subsidiary Teneobio willfully infringed on a foundational antibody discovery patent held by Harbour BioMed. The verdict, delivered after a brief three-hour deliberation, awards the biopharmaceutical company $20.2 million and validates the integrity of its proprietary transgenic rodent technology.



















